Nuvei: BMO Raises Price Target To $59 Following Preliminary Results

On February 5th, Nuvei Corp (TSX: NVEI) announced preliminary fourth-quarter numbers. They announced total revenue to be between $114 – $118 million, EBITDA between $50 – $52 million, and an operating profit between $16.5 – $19.5 million.

Nuvei currently has 13 analysts covering the company with a weighted 12-month price target of $65. This is up from the average at the end of January, which was $54.87. Only one analyst has a strong buy rating, while eight have buy ratings, and the last four analysts have hold ratings.

Below are the analyst changes since the news release:

  • Scotiabank raises target price to C$83 from C$71
  • CIBC raises target price to C$90 from C$76

On the 5th, BMO Capital Markets analyst James Fotheringham raised their 12-month price target to C$59 from C$57 and reiterated their market perform rating. He writes, “Following NVEI’s 4Q20 positive pre-announcement, we raise our estimates by up to 13% due to higher expected revenues (from faster volume growth and mix shift to more e-commerce business).” He adds that Nuvei is exceptionally positioned for the e-commerce growth that has been accelerated by the pandemic but worries that with the stock being up 120% from IPO, about “the vulnerability of its valuation multiple.”

Nuvei’s implied core earnings per share are $0.24, which is 20% above BMO’s estimate, while revenue and EBITDA are coming in much higher and Fotheringham writes, “revenues appear driven by faster volume growth (partly offset by a lower take rate).” He adds that the fourth quarter volume growth is 50% year over year, while e-commerce accounts for 80% of total volume. He writes, “We expect e-commerce volume growth to remain elevated throughout 1H21E, then moderate in 2H21E as activity normalizes.”

Below you can see BMO’s key changes to full-year 2020 and 2021 estimates. Fotheringham comments, “We raise our NVEI core EPS estimates by 11% in 2020E (to $0.46 from $0.41), 13% in 2021E (to $1.05 from $0.93), and 11% in 2022E (to $1.20 from $1.08); higher than previously-modeled revenues more than offset higher expected operating costs.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Total Metals Secures High Grade Critical Minerals Property In Northwestern Ontario

Discovery at Luis Hill Prompts Acceleration of Phase 2 Program for Questcorp

Related News

Hive Blockchain: Canaccord Remains Positive On Outlook

On August 26th, Canaccord Genuity Capital Markets’ raised their 12-month price target on Hive Blockchain...

Monday, August 29, 2022, 02:22:00 PM

K92 Mining: Canaccord Initiates Coverage With $8.75 Price Target

On January 31st, Canaccord Genuity Capital Markets initiated coverage on K92 Mining Inc. (TSX: KNT),...

Thursday, February 3, 2022, 04:29:00 PM

Sundial Growers: Canaccord Raises Price Target Due To Strong Balance Sheet

Sundial Growers (NASDAQ: SNDL) reported its second quarter financial results on August 12. The company...

Tuesday, August 17, 2021, 03:35:00 PM

Valens: Canaccord Maintains $3.50 Price Target Following First Quarter Results

Last week, The Valens Company (TSX: VLNS) reported first quarter financial results. The company reported...

Saturday, April 17, 2021, 12:05:00 PM

PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target

PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th....

Wednesday, June 30, 2021, 02:38:00 PM